Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H18N2O4S |
Molecular Weight | 370.422 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=C(C=C1OCC)C2=NC(=CS2)C3=NC(=CC=C3)C(O)=O
InChI
InChIKey=XDBHURGONHZNJF-UHFFFAOYSA-N
InChI=1S/C19H18N2O4S/c1-3-24-16-9-8-12(10-17(16)25-4-2)18-21-15(11-26-18)13-6-5-7-14(20-13)19(22)23/h5-11H,3-4H2,1-2H3,(H,22,23)
Otsuka Pharmaceutical Co developed tetomilast, a thiazole derivative for the treatment of inflammatory bowel disease and chronic obstructive pulmonary disease. Tetomilast acts as a selective inhibitor of phosphodiesterase-4 results in increased intracellular levels of cyclic adenosine monophosphate (cAMP), and subsequent anti-inflammatory effects. Specifically, the release of pro-inflammatory mediators including TNF-a and IL-12 is suppressed, and there is stimulation of the release of anti-inflammatory mediators including IL-10 and prostaglandin E2. Unfortunately, tetomilast clinical trials in patients with ulcerative colitis failed to demonstrate superior efficacy compared to mesalamine and further development of tetomilast was discontinued.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23043390 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17241861
50 mg/day for 8 weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C744
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034425
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY | |||
|
3025803
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL332750
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY | |||
|
C90922
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY | |||
|
DTXSID00163149
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY | |||
|
C108965
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY | |||
|
145739-56-6
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY | |||
|
S6RXB5KF56
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY | |||
|
DB05298
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY | |||
|
8430
Created by
admin on Fri Dec 15 16:52:34 GMT 2023 , Edited by admin on Fri Dec 15 16:52:34 GMT 2023
|
PRIMARY |
ACTIVE MOIETY